Recently, many molecular targeted agents have been approved for u-HCC, and by considering pretreatment factors including liver function (ALBI score), AFP level, and MVI we can construct useful therapeutic strategies for patients with unresectable HCC. The gene discussed is AFP; the disease is hepatocellular carcinoma.